Researchers discover master regulator that drives majority of lymphoma
A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein. However, a research team, led by investigators at Weill Cornell ...
Cancer
May 13, 2013 |
5 / 5 (3) |
0
|
Researchers find NSAIDs help push stem cells into bloodstream prior to transplantation
(Medical Xpress)—A team of researchers at Indiana University's School of Medicine has found that giving meloxicam, a non-steroidal anti-inflammatory drug (NSAID), to people and baboons boosts the number of haematopoietic ...
Medical research
Mar 14, 2013 |
not rated yet |
0
|
Small molecules in the blood might gauge radiation effects after exposure
Ohio State University cancer researchers have identified molecules in the bloodstream that might accurately gauge the likelihood of radiation illness after exposure to ionizing radiation.
Cancer
Feb 25, 2013 |
5 / 5 (1) |
0
|
Epigenomic abnormalities predict patient survival in non-Hodgkins lymphoma
Think of the epigenome like a giant musical mixing board, turning up or down the expression of various genes. A University of Colorado Cancer Center study published today in the journal PLOS Genetics shows that in cancer ...
Genetics
Jan 10, 2013 |
not rated yet |
0
|
Drug shortage linked to greater risk of relapse in young Hodgkin lymphoma patients
A national drug shortage has been linked to a higher rate of relapse among children, teenagers and young adults with Hodgkin lymphoma enrolled in a national clinical trial, according to research led by St. Jude Children's ...
Cancer
Dec 26, 2012 |
not rated yet |
0
|
Novel test identifies patients most likely to benefit from ALK inhibition therapy
Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for treatment because these patients ...
Medical research
Dec 12, 2012 |
not rated yet |
0
|
Novel drug therapy targets aggressive form of non-Hodgkin's lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell – DLBCL ...
Cancer
Dec 10, 2012 |
not rated yet |
0
|
Genome sequencing of Burkitt Lymphoma reveals unique mutation
In the first broad genetic landscape mapped of a Burkitt lymphoma tumor, scientists at Duke Medicine and their collaborators identified 70 mutations, including several that had not previously been associated with cancer and ...
Genetics
Nov 12, 2012 |
5 / 5 (1) |
0
|
Scientists harness immune system to prevent lymphoma relapse
UK scientists hope that lymphoma patients could benefit from a new drug that triggers the cancer-fighting properties of the body's own immune system, after highly promising early laboratory results.
Cancer
Oct 18, 2012 |
not rated yet |
0
|
Many options, good outcomes, for early-stage follicular lymphoma
(Medical Xpress) -- A University of Rochester Medical Center study challenges treatment guidelines for early stage follicular lymphoma, concluding that six different therapies can bring a remission, particularly if the patient ...
Cancer
Aug 21, 2012 |
not rated yet |
0
|
B cell survival holds key to chronic graft vs. host disease
Leukemia and lymphoma patients who receive life-saving stem cell or bone marrow transplants often experience chronic side effects that significantly decrease quality of life, can last a lifetime, and ultimately affect their ...
Diseases, Conditions, Syndromes
Aug 16, 2012 |
not rated yet |
0
|
New drug dramatically improves survival in Hodgkin lymphoma patients
A new cancer drug with remarkably few side effects is dramatically improving survival in Hodgkin lymphoma patients who fail other treatments and are nearly out of options.
Cancer
Jun 27, 2012 |
5 / 5 (1) |
0
|
Progress in quest to reduce use of radiation in treatment of pediatric Hodgkin lymphoma
A multicenter trial showed that nearly half of young patients with early-stage Hodgkin lymphoma can be cured without undergoing either irradiation or intensive chemotherapy that would leave them at risk for second cancers, ...
Cancer
Jun 26, 2012 |
not rated yet |
0
|
'Rediscovered' lymphoma drug helps double survival: study
(HealthDay) -- A drug first developed in East Germany in the 1960s has re-emerged as a potent "new" weapon against certain types of non-Hodgkin lymphomas, researchers report.
Cancer
Jun 04, 2012 |
5 / 5 (1) |
0
|
New therapy on the horizon for ALK+ non-small cell lung cancer
A new compound that targets anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer is well-tolerated by patients and is already showing early signs of activity, including in patients who no longer respond to ...
Cancer
Jun 01, 2012 |
not rated yet |
0
|
